Connor Clark & Lunn Investment Management Ltd. Purchases 102,195 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Connor Clark & Lunn Investment Management Ltd. boosted its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 22.5% during the fourth quarter, Holdings Channel reports. The fund owned 556,454 shares of the biotechnology company’s stock after acquiring an additional 102,195 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Aurinia Pharmaceuticals were worth $4,997,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $25,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Aurinia Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 2,857 shares during the last quarter. FMR LLC grew its stake in shares of Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 3,919 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Aurinia Pharmaceuticals by 61.9% during the fourth quarter. US Bancorp DE now owns 19,366 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 7,406 shares during the period. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $8.16 on Monday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average of $8.01 and a 200-day moving average of $7.94. The firm has a market cap of $1.12 billion, a P/E ratio of -54.40 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 8,305 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the sale, the insider now directly owns 153,484 shares in the company, valued at $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Peter Greenleaf sold 195,593 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now owns 1,953,892 shares of the company’s stock, valued at $15,631,136. This trade represents a 9.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 343,898 shares of company stock worth $2,753,094. Company insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.